Use of mitomycin C in repeat dacryocystorhinostomy

Ophthalmic Plast Reconstr Surg. 1999 Jan;15(1):19-22. doi: 10.1097/00002341-199901000-00005.


Purpose: The usefulness of a single intraoperative application of mitomycin C was investigated in repeat dacryocystorhinostomy for membranous failure.

Methods: Mitomycin C (0.3 mg/ml for 3 minutes) was topically applied to the fistula site in eight patients undergoing repeat dacryocystorhinostomy for membranous failure.

Results: All patients remain asymptomatic and anatomic patency confirmed by probe and irrigation with a mean follow-up period of 14.6 months (range, 6-26 months). No postoperative complications associated with the use of mitomycin C were observed.

Conclusions: In patients who do not maintain a patent fistula after dacryocystorhinostomy because of membranous occlusion of the rhinostomy site, the adjunctive use of mitomycin C may increase the success rate of repeat dacryocystorhinostomy.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / therapeutic use*
  • Dacryocystorhinostomy*
  • Female
  • Humans
  • Lacrimal Duct Obstruction / drug therapy*
  • Male
  • Middle Aged
  • Mitomycin / administration & dosage
  • Mitomycin / therapeutic use*
  • Reoperation
  • Treatment Outcome


  • Antibiotics, Antineoplastic
  • Mitomycin